Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM457XO)

Drug Name

IW-1701 Drug Info

Synonyms

Olinciguat; 1628732-62-6; UNII-PD5F4ZXD21; PD5F4ZXD21; IW1701; 5-(1,2-oxazol-3-yl)-1H-pyrazol-; 3-yl}pyrimidin-4-yl)amino]methyl}-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-{[(5-fluoro-2-{1-[(2-fluorophenyl)methyl]-; Olinciguat [INN]; Olinciguat [USAN]; Olinciguat (USAN/INN); Olinciguat [USAN:INN]; CHEMBL4297616; SCHEMBL16081945; GTPL10213; BDBM321744; DB15238; US10183021, Compound I-531; AC-31551; HY-109066; CS-0033431; D11475; (2~{R})-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide; (2R)-3,3,3-trifluoro-2-[[[5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]pyrimidin-4-yl]amino]methyl]-2-hydroxypropanamide

Indication

Disease Entry	ICD 11	Status	REF
Sickle-cell disorder	3A51	Phase 2	[1]

Cross-matching ID

PubChem CID: 90445883
CAS Number: CAS 1628732-62-6
TTD Drug ID: DM457XO

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Guanylate cyclase (GC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nitric Oxide	DM1RBYG	Respiratory failure	CB41	Approved	[3]
Isosorbide dinitrate	DMBI4JG	Anal fissure	DB50.0	Approved	[3]
Methylene blue	DMJAPE7	Acquired methemoglobinemia	3A93	Approved	[4]
Isosorbide mononitrate	DMYLMU0	Hydrocephalus	8D64	Approved	[3]
Erythrityl Tetranitrate	DMFGQ2S	Angina pectoris	BA40	Approved	[3]
Pirsidomine	DMHI6GE	Angina pectoris	BA40	Phase 2	[5]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Guanylate cyclase (GC)	TT6HPVC	NOUNIPROTAC	Stimulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03285178) A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD) (STRONG SCD). U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of Cyclerion Therapeutics.
3	Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2010 Jan;333(1-2):191-201.
4	Curcumin ameliorates high glucose-induced acute vascular endothelial dysfunction in rat thoracic aorta. Clin Exp Pharmacol Physiol. 2009 Dec;36(12):1177-82.
5	Activation of soluble guanylyl cyclase by the nitrovasodilator 3-morpholinosydnonimine involves formation of S-nitrosoglutathione. Mol Pharmacol. 1998 Jul;54(1):207-12.